Khiron Life Sciences Announced as Co-Host of Cannamexico World Summit 2019
Andres Galofre, Khiron Co-founder and Vice-president of Business Development appointed to Cannamexico Board of Directors
TORONTO, Jan. 17, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company will co-host Cannamexico World Summit 2019, a comprehensive cannabis symposium taking place April 25 - 26 at Centro Fox, Guanajuato, Mexico. This is the second annual Cannamexico event and is recognized as the first of its kind cannabis summit in Mexico.
Companies in the fields of science, research, finance, medicine, government, technology, innovation, agro-industry and entrepreneurship, among others, will participate at the event in open discussions about medical cannabis. Khiron will be prominently featured throughout the summit and key members of the Company's senior management, medical and compliance team will deliver session presentations on medical cannabis patient, research and compliance topics, with particular focus in Latin America.
Former Mexican President and Khiron Board Member, Mr. Vicente Fox stated, "The debate on the legalization of cannabis is an agenda priority in Mexico and this event has assumed the historic responsibility of being a place that converges ideas and developments on public policies that contribute to our country, raising the voice on important issues regarding cannabis legislation, cultivation and commercialization."
Cannamexico World Summit 2019 will bring together more than 2,000 attendees from across the region, connecting the cannabis community with national and international experts on priority topics, including:
- Regulatory Framework
- Eco-growth: Sustainable view
- Medicine & Science
- Pain reduction
- Industry Opportunities
Andres Galofre, Vice-president of Business Development and Cannamexico board member commented "We are proud and honoured to have a partnership with Centro Fox and to have the opportunity to sponsor the Cannamexico World Summit 2019. As a member of the Cannamexico Board of Directors I will continue to advocate and raise awareness regarding the potential for the cannabis industry in Mexico."
As previously announced, Khiron is strategically positioned to enter the Mexican market with the launch of its first nutraceutical product line and establishing a subsidiary in the country to submit license applications, completing an in-depth regulatory review of the country's legal medical cannabis landscape as well as an assessment of market needs. Mexico comprises a population of approximately 123.5 million people, with nearly 11.7 million potential patients for medical cannabis.
International Summit focused on showing the potential of the Cannabis industry in Mexico, which seeks to provide information on legal regulations, market opportunities, medical advances, innovation, and wellness.
For more information visit the website: http://cannamexico.com.mx/en
Khiron Life Sciences Corp. is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming one of the first Colombian based medical cannabis companies to trade on any exchange globally.
With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found at https://investors.khiron.ca/
Market and Industry Data
This press release contains market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of included information. Although management believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this press release, or analyzed or verified the underlying studies or surveys relied upon or referred to by such sources, or ascertained the underlying economic assumptions relied upon by such sources.
This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements may be identified by statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Forward-looking statements herein include, but are not limited to, statements regarding the final acceptance of the TSXV and the commencement of sales in Mexico. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.
For further information: Investor Contacts: Chris Naprawa, President, T: +1 (416) 705-1144, E: firstname.lastname@example.org; Darren Collins, Chief Financial Officer, T: +1 (705) 527-3564, E: email@example.com; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: firstname.lastname@example.org
Released January 17, 2019